Pasithea Therapeutics (KTTA) Current Assets (2020 - 2026)
Pasithea Therapeutics (KTTA) posted Current Assets of $52.7 million for Q1 2026, down 6.6% sequentially from $56.5 million in Q4 2025, and up 760.93% YoY from $6.1 million in Q1 2025.
Pasithea Therapeutics (KTTA) Current Assets (2020 - 2026) Analysis & Trends
Pasithea Therapeutics has reported Current Assets for 7 years, with the latest figure at $52.7 million in Q1 2026.
- Quarterly Current Assets rose 760.93% year-over-year to $52.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $52.7 million (up 760.93% YoY) and the FY2025 annual result came in at $56.5 million, up 666.24% from the prior year.
- Current Assets eased to $52.7 million in Q1 2026 per KTTA's latest filing, from $56.5 million in the prior quarter.
- Over five years, Current Assets peaked at $56.5 million in Q4 2025 and troughed at $5.5 million in Q3 2025.
- A 5-year average of $26.1 million and a median of $20.8 million in 2023 frame the typical range for Current Assets.
- The sharpest annual moves came in 2024 and 2026: Current Assets tumbled 69.17% in 2024, then jumped 760.93% in 2026.
- Over 5 years, Current Assets stood at $34.1 million in 2022, then plunged by 51.02% to $16.7 million in 2023, then plunged by 55.86% to $7.4 million in 2024, then soared by 666.24% to $56.5 million in 2025, then dropped by 6.6% to $52.7 million in 2026.
- According to Business Quant data, Current Assets over the past three periods registered $52.7 million, $56.5 million, and $5.5 million for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.79 Bn | 130.93 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 85.99 Bn | 78.00 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 65.26 Bn | 60.07 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 56.04 Bn | 50.91 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 42.05 Bn | 36.95 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 31.71 Bn | 28.40 Bn | 992.69 Mn | 4.62 Bn |
| 7 | BioNTech SE | 27.66 Bn | 9.26 Bn | 668.28 Mn | 18.80 Bn |
| 8 | Insmed | 27.50 Bn | 26.33 Bn | 358.27 Mn | 1.63 Bn |
| 9 | Royalty Pharma | 27.35 Bn | 26.52 Bn | - | 1.76 Bn |
| 10 | Pasithea Therapeutics | 16.07 Mn | 16.07 Mn | - | 48.24 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 52.73 Mn |
| Dec 31, 2025 | 56.46 Mn |
| Sep 30, 2025 | 5.53 Mn |
| Jun 30, 2025 | 8.64 Mn |
| Mar 31, 2025 | 6.12 Mn |
| Dec 31, 2024 | 7.37 Mn |
| Sep 30, 2024 | 9.78 Mn |
| Jun 30, 2024 | 8.64 Mn |
| Mar 31, 2024 | 13.19 Mn |
| Dec 31, 2023 | 16.69 Mn |
| Sep 30, 2023 | 20.77 Mn |
| Jun 30, 2023 | 28.04 Mn |
| Mar 31, 2023 | 31.11 Mn |
| Dec 31, 2022 | 34.08 Mn |
| Sep 30, 2022 | 44.47 Mn |
| Jun 30, 2022 | 48.61 Mn |
| Mar 31, 2022 | 50.95 Mn |
| Dec 31, 2021 | 53.30 Mn |
| Sep 30, 2021 | 21.03 Mn |
| Dec 31, 2020 | 247,958.00 |